Home Other Building Blocks 413599-62-9
413599-62-9
Catalog No.:AA01FPBY

413599-62-9 | ZD-4190

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
95%
1 week  
$204.00   $143.00
- +
2mg
95%
1 week  
$277.00   $194.00
- +
5mg
95%
1 week  
$426.00   $298.00
- +
10mg
95%
1 week  
$610.00   $427.00
- +
25mg
95%
1 week  
$936.00   $656.00
- +
50mg
95%
1 week  
$1,258.00   $880.00
- +
100mg
95%
1 week  
$1,680.00   $1,176.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA01FPBY
Chemical Name:
ZD-4190
CAS Number:
413599-62-9
Molecular Formula:
C19H16BrFN6O2
Molecular Weight:
459.2717
SMILES:
COc1cc2c(ncnc2cc1OCCn1nncc1)Nc1ccc(cc1F)Br
Properties
Computed Properties
 
Complexity:
523  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
29  
Hydrogen Bond Acceptor Count:
8  
Hydrogen Bond Donor Count:
1  
Rotatable Bond Count:
7  
XLogP3:
3.5  

Literature

Title: PET imaging of early response to the tyrosine kinase inhibitor ZD4190.

Journal: European journal of nuclear medicine and molecular imaging 20110701

Title: The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissues.

Journal: British journal of cancer 20090804

Title: Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20090101

Title: Inhibition of vascular endothelial growth factor (VEGF)-165 and semaphorin 3A-mediated cellular invasion and tumor growth by the VEGF signaling inhibitor ZD4190 in human colon cancer cells and xenografts.

Journal: Molecular cancer therapeutics 20060801

Title: Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media.

Journal: Magnetic resonance imaging 20031001

Title: Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts.

Journal: Magnetic resonance imaging 20030601

Title: Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.

Journal: Journal of medicinal chemistry 20020314

Title: Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.

Journal: Journal of medicinal chemistry 19991230

Title: Yang M, et al. PET imaging of early response to the tyrosine kinase inhibitor ZD4190. Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1237-47. doi: 10.1007/s00259-011-1742-z. Epub 2011 Mar 1.

Title: Gaballah K, et al. The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissues. Br J Cancer. 2009 Aug 4;101(3):418-23. doi: 10.1038/sj.bjc.6605092. Epub 2009 Jul 21.

Title: Checkley D, et al. Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts. Magn Reson Imaging. 2003 Jun;21(5):475-82.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 413599-62-9
Tags:413599-62-9 Molecular Formula|413599-62-9 MDL|413599-62-9 SMILES|413599-62-9 ZD-4190